
    
      A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of
      Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by
      Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous
      Cell Carcinoma of the Head and Neck (SCCHN)
    
  